Avandia And Actos Add “Black Boxes” For Heart Failure
Executive Summary
As an interim step in its ongoing review of thiazolidinedione cardiac safety, FDA has called for revised class labeling for the TZDs featuring strengthened warnings about the incidence of heart failure and contraindications for patients with existing heart failure
You may also be interested in...
Avandia Retaining Preferred Status On 2008 Part D Formularies – For Now
So far GlaxoSmithKline's Avandia (rosiglitazone) appears to be retaining its tier 2 status on the 2008 formularies of major Medicare Part D plans despite safety concerns that surfaced earlier this year
Avandia Retaining Preferred Status On 2008 Part D Formularies – For Now
So far GlaxoSmithKline's Avandia (rosiglitazone) appears to be retaining its tier 2 status on the 2008 formularies of major Medicare Part D plans despite safety concerns that surfaced earlier this year
Actos Generics Should Await Expiration Of All Patented Uses, Takeda Tells FDA
Approving generic versions of Takeda's Actos for use as monotherapy prior to expiration of its combination-use patents would hinder the safe and effective use of the diabetes drug, the firm says in a petition to FDA